- Home
- Publications
- Publication Search
- Publication Details
Title
Peginterferon α-2a for the treatment of HIV infection
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 25, Issue 2, Pages 249-257
Publisher
Informa Healthcare
Online
2015-12-15
DOI
10.1517/13543784.2016.1132699
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Select host restriction factors are associated with HIV persistence during antiretroviral therapy
- (2015) Mohamed Abdel-Mohsen et al. AIDS
- Lysis of HIV-1-infected autologous CD4+ primary T cells by interferon-alpha-activated NK cells requires NKp46 and NKG2D
- (2015) Costin Tomescu et al. AIDS
- Hepatitis C therapy with interferon-α and ribavirin reduces the CD4 cell count and the total, 2LTR circular and integrated HIV-1 DNA in HIV/HCV co-infected patients
- (2015) Yan-mei Jiao et al. ANTIVIRAL RESEARCH
- Blockade of Interferon Beta, but Not Interferon Alpha, Signaling Controls Persistent Viral Infection
- (2015) Cherie T. Ng et al. Cell Host & Microbe
- Brief Report
- (2015) María Abad-Fernández et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling
- (2015) Stephan Wilmes et al. JOURNAL OF CELL BIOLOGY
- HIV-1 and interferons: who's interfering with whom?
- (2015) Tomas Doyle et al. NATURE REVIEWS MICROBIOLOGY
- IFI44 suppresses HIV-1 LTR promoter activity and facilitates its latency
- (2015) Derek Power et al. VIROLOGY
- Inhibition of the OAS/RNase L pathway by viruses
- (2015) Melissa Drappier et al. Current Opinion in Virology
- Type I Interferon: Understanding Its Role in HIV Pathogenesis and Therapy
- (2015) Steven E. Bosinger et al. Current HIV/AIDS Reports
- The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis
- (2015) Qiao-Ling Xie et al. PLoS One
- Long-term control of HIV replication with dolutegravir and pegylated interferon alpha-2a in an HIV-infected patient with sixtuple-class resistance
- (2014) M Luisa Montes et al. AIDS
- Pharmacokinetics and Pharmacodynamics of Antiretrovirals in the Central Nervous System
- (2014) Andrea Calcagno et al. CLINICAL PHARMACOKINETICS
- Host and Viral Determinants of Mx2 Antiretroviral Activity
- (2014) Idoia Busnadiego et al. JOURNAL OF VIROLOGY
- Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression
- (2014) Netanya G. Sandler et al. NATURE
- Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues
- (2014) Courtney V. Fletcher et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue
- (2013) Nicolette A. Louissaint et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Hepatitis C Therapy With Interferon-α and Ribavirin Reduces CD4 T-Cell–Associated HIV-1 DNA in HIV-1/Hepatitis C Virus–Coinfected Patients
- (2013) Hong Sun et al. JOURNAL OF INFECTIOUS DISEASES
- Evidence for Innate Immune System Activation in HIV Type 1–Infected Elite Controllers
- (2013) Sonya Krishnan et al. JOURNAL OF INFECTIOUS DISEASES
- Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection
- (2013) Caroline Goujon et al. NATURE
- Continuous versus intermittent treatment strategies during primary HIV-1 infection
- (2012) Cécile Goujard et al. AIDS
- Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation
- (2012) Jacob Piehler et al. IMMUNOLOGICAL REVIEWS
- Host Gene Expression Changes Correlating With Anti–HIV-1 Effects in Human Subjects After Treatment With Peginterferon Alfa-2a
- (2012) Jonathan J. Hubbard et al. JOURNAL OF INFECTIOUS DISEASES
- Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration
- (2012) Livio Azzoni et al. JOURNAL OF INFECTIOUS DISEASES
- Role of retroviral restriction factors in the interferon- -mediated suppression of HIV-1 in vivo
- (2012) S. K. Pillai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN)
- (2011) C. Tomescu et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- CD4+ T-Cell Deficiency in HIV Patients Responding to Antiretroviral Therapy Is Associated With Increased Expression of Interferon-Stimulated Genes in CD4+ T Cells
- (2011) Sonia Fernandez et al. JOURNAL OF INFECTIOUS DISEASES
- Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral Therapy
- (2011) Tae-Wook Chun et al. JOURNAL OF INFECTIOUS DISEASES
- IFIT1 is an antiviral protein that recognizes 5′-triphosphate RNA
- (2011) Andreas Pichlmair et al. NATURE IMMUNOLOGY
- Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
- (2011) K. B. Patterson et al. Science Translational Medicine
- Safety, Tolerability, and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa‐2a in HIV‐1–Monoinfected Participants: A Phase II Clinical Trial
- (2010) David M. Asmuth et al. JOURNAL OF INFECTIOUS DISEASES
- CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-α: relationship to CNS immune responses and depression
- (2009) C L Raison et al. MOLECULAR PSYCHIATRY
- Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu
- (2008) Stuart J. D. Neil et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started